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Abstract
Objective To determine whether quantitative multivoxel
MRS improves the accuracy of MRI in the assessment of
breast lesions.
Methods Twenty-five consecutive patients with 26 breast
lesions ≥1 cm assessed as BI-RADS 3 or 4 with
mammography underwent quantitative multivoxel MRS
and contrast-enhanced MRI. The choline (Cho) concentra-
tion was calculated using the unsuppressed water signal as
a concentration reference. ROC analysis established the
diagnostic accuracy of MRI and MRS in the assessment of
breast lesions.
Results Respective Cho concentrations in 26 breast lesions
re-classified by MRI as BI-RADS 2 (n=5), 3 (n=8), 4 (n=
5) and 5 (n=8) were 1.16±0.43 (mean±SD), 1.43±0.47,
2.98±2.15 and 4.94±3.10 mM. Two BI-RADS 3 lesions
and all BI-RADS 4 and 5 lesions were malignant on
histopathology and had Cho concentrations between 1.7
and 11.8 mM (4.03±2.72 SD), which were significantly
higher (P=0.01) than that in the 11 benign lesions (0.4–
1.5 mM; 1.19±0.33 SD). Furthermore, Cho concentrations in
the benign and malignant breast lesions in BI-RADS 3
category differed (P=0.01). The accuracy of combined multi-
voxel MRS/breast MRI BI-RADS re-classification (AUC=
1.00) exceeded that of MRI alone (AUC=0.96±0.03).
Conclusions These preliminary data indicate that multi-
voxel MRS improves the accuracy of MRI when using
a Cho concentration cut-off ≤1.5 mM for benign
lesions.
Key Points
• Quantitative multivoxel MR spectroscopy can improve the
accuracy of contrast-enhanced breast MRI.
• Multivoxel-MRS can differentiate breast lesions by using
the highest Cho-concentration.
• Multivoxel-MRS can exclude patients with benign breast
lesions from further invasive diagnostic procedures.
Keywords Magnetic resonance imaging . Spectroscopy .
Chemical shift imaging . Breast . Choline
Introduction
Breast magnetic resonance imaging (MRI) has emerged as
an important diagnostic technique. With the use of
morphological characteristics and kinetic analysis of the
uptake of contrast agents in breast lesions on MRI, the
sensitivity of breast MRI approaches 90% whereas the
overall specificity of breast MRI varies between 67% and
72% [1–3]. Although the negative predictive value (NPV)
of MRI in breast cancer is the highest of all imaging
techniques (97%) [4–6], meaning that in most cases a
negative breast MRI can safely rule out malignancy, breast
MRI alone is still not the perfect technique.
The fourth edition of the Breast Imaging Reporting and
Data System (BI-RADS) Atlas includes a new lexicon for
breast MRI that promotes the standardisation of lesion
descriptors and assessment categories [7]. This lexicon is
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based on the results of the International Working Group on
Breast MRI and the American College of Radiology (ACR)
Breast MRI Lexicon Committee and includes a BI-RADS 3
assessment category [7–10]. The guidelines for non-
invasive diagnostic tests for breast abnormalities of the
Agency for Health Care Research and Quality in the United
States (AHRQ) state that the work-up of these probably
benign findings is a short-term follow-up or biopsy [11]. At
this moment most approaches are intuitive [11, 12]. It can
be expected that most patients thus referred for biopsy have
a benign lesion.
In addition to morphological and kinetic analysis,
metabolic information is considered useful for the assess-
ment of breast lesions. A promising approach to clarifying
the precise nature (benign or malignant) of a lesion is the
use of a non-invasive MRI method which is referred to as
MR spectroscopy [13, 14]. The diagnostic value of MR
spectroscopy is typically based on the detection of elevated
levels of choline (Cho) compounds. MR spectroscopic
studies of the breast have been either single-voxel [13–33]
or multivoxel [34–40] investigations. The single-voxel
technique has limitations in terms of lesion coverage. The
general practice of including either the entire lesion or just
its centre in the voxel, may result in the dilution of the
elevated Cho levels in vital malignant tumours by the
contributing necrotic and cystic tumour areas with low Cho
levels, resulting in false-negative results [34, 38].
The multivoxel MR spectroscopic technique [also
known as chemical-shift imaging (CSI)] acquires spectro-
scopic information from a large volume of interest
subdivided into an array of voxels and has the potential to
perform truly quantitative tissue characterisation [34–40].
This is necessary because Cho signals are not only detected
in malignant breast lesions but also in benign breast lesions
and normal fibroglandular tissues [13, 14, 17, 23, 25, 36].
Recently, multivoxel MR spectroscopy was used to
measure Cho concentrations encountered in breast lesions
[38].
The purpose of this study is to determine whether the
Cho level measured by quantitative multivoxel MR
spectroscopy can increase the accuracy of contrast-
enhanced MRI in the assessment of breast lesions.
Materials and methods
Patient population
This prospective study was conducted between July 2009
and July 2010 at the University Medical Center Groningen
and was approved by the Medical Ethical Committee of the
University of Groningen. Informed consent was obtained
from each patient before participation in the study.
Twenty-five consecutive patients (mean age: 48.7 years,
age range: 32–69) with 26 breast lesions ≥1 cm assessed as
BI-RADS 3 or BI-RADS 4 with mammography underwent
multivoxel MR spectroscopy and contrast-enhanced MRI.
Patients were excluded if there was a history of breast
cancer, a haematoma of the breast or previous breast
surgery including breast implants. The final diagnosis of
the breast lesions was based on cytology or histology,
considered the gold standard. Tissue samples were obtained
by ultrasound-guided fine needle aspiration biopsy (FNAB)
(n=3), ultrasound-guided core biopsy (n=5), MR-guided
vacuum-assisted core biopsy (n=1) or surgery (n=17).
MR imaging
Magnetic resonance imaging was performed at 1.5 T using
a whole-body MRI system (Avanto; Siemens Medical
Solutions, Erlangen, Germany) with a dedicated bilateral
breast coil and the patient in the prone position. The
standard MRI protocol included diffusion-weighted imag-
ing (DWI) with b-values 0, 50, 200, 500, 800 and 1000 s/
mm2. A T2-weighted turbo spin echo [repetition time (TR)/
echo time (TE) 4500/102 ms, FOV 340 mm and slice
thickness 4 mm] was performed in the transversal plane. A
T1-weighted three-dimensional (3D) DynaVIEWS se-
quence (TR/TE/FA 4.17 ms/1.29 ms/10°, FOV 340 mm
and slice thickness 0.97 mm, in total 1.04 min) in the
transversal plane was made before and seven times after
intravenous administration of 0.1 mmol/kg DOTAREM
(0.5 mmol Gd/mL). The total duration of the dynamic study
was approximately 9 min.
Multivoxel MR spectroscopy
The breast lesion was localised on DWI and T2-weighted
MR images. After the location of the breast lesion was
determined, the transverse and sagittal T2-weighted fast
spin-echo series covering both breasts (TR/TE 4500/
102 ms) performed without distortion correction were used
for MR spectroscopy planning. The spectroscopic imaging
protocol [38] included 2D-CSI with point-resolved spec-
troscopy (PRESS) double spin-echo with phase-encoding
gradients between the slice selective 90° pulse and the first
slice-selective optimised 180° pulse. 2D-CSI of the breast
was performed twice, first without suppression of the water
and fat signals (TR/TE 1500/30 ms) to serve as a reference
measurement. The second measurement was with suppres-
sion of the water and fat signals (TR/TE 1500/135 ms) and
with the same receiver gain. The center of k-space was
sampled six times in a weighted elliptical fashion resulting
in an acquisition time of 4.46 min. The field of view was
8×8 cm2 to roughly cover the transverse cross-section of
the examined breast, subdivided into 144 phase encode
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steps to yield voxels of 0.67×0.67×1 cm3 at a slice
thickness of 1 cm. In this hybrid CSI technique the volume
of interest (VOI), positioned over the suspect lesion, was
smaller than the field of view (3×3×1 cm3) in order to end
up with essentially measuring the watery part of the breast
(glandular breast tissue, histopathology). Six additional
nine-lobe sinc outer volume suppression pulses were
applied before excitation, resulting in six outer volume
suppression slabs of at least 3-cm thick on all sides of the
VOI, and unwanted water and lipid signals were suppressed
by band-selective inversion with gradient dephasing (BAS-
ING) [38]. Automated volume selective (linear plus higher
order) shimming resulted in water-signal linewidths of 6 to
9 Hz for voxels within the VOI.
The multivoxel MR spectroscopy was performed before
the T1-weighted images with contrast medium administra-
tion to prevent possible interference of metal chelate with
the detectability of Cho [41, 42].
Data analysis
MR imaging
Subtracted images were obtained by subtracting pre-
contrast images from the post-contrast images using
commercially available software (CADstream, Confirma
Inc., Kirkland WA, USA). MRI were coded using the
ordered categories of the ACR BI-RADS lexicon [7]. The
MR images were classified as normal if no enhancement
was seen in the expected location of the mammographic
finding (BI-RADS 1) or if only homogeneous or stippled
enhancement was found in the breast, representing normal
enhancing breast parenchyma or fibrocystic changes (BI-
RADS 2). The lesions that were detected on the MRI and
which corresponded with the area of the mammographic
findings were assessed as focus, mass enhancement or non-
mass like enhancement. For the enhancing lesions the
location, lesion type, shape, border, distribution, internal
enhancement and kinetic curves according to the BI-RADS
lexicon were assessed and the lesions were classified as BI-
RADS 3, 4 or 5 [7].
Multivoxel MR spectroscopy
In the post-processing 12×12 phase, encode steps were
interpolated into a 16×16 matrix, i.e. voxels appearing as
0.5×0.5×1 cm3. The number of MR spectroscopic peaks
fitted included the chemical shift ranges restricted to 3.1–
3.3 ppm for Cho, 4.5–5.0 ppm for water and 1.0–1.5 ppm
for the main resonance of fat (−CH2-). Standardised
postprocessing protocols were used for processing the raw
data automatically, allowing for operator-independent quan-
tifications. The postprocessing protocol for the water and
fat suppressed series included Hanning filtering (width
700 ms, center 0 ms), zero filling from 512 to 1024 data
points, Fourier transformation, polynomial baseline correc-
tion (with the above peak ranges excluded), phase
correction and frequency-domain curve fitting to Gaussian
lineshapes using the standard Singo software provided by
the manufacturer of the MRI system.
For each lesion the highest concentration of the
metabolite Cho amongst the various corresponding voxels
was calculated from the relative peak areas of the
resonances of Cho [N(CH3)3 at 3.23 ppm], denoted SCho,
and water (H2O at 4.7 ppm) using Eq. (1):
SCho½  ¼ SCho=SH2O  TWC 1=MwH2O  nH2O=nCho
T1satH2O=T1satCho  T2satH2O=T2satCh
ð1Þ
To express concentrations in molar units (mol/L of tissue
volume), literature values were adapted for the tissue water
contents (TWC) of voxels containing breast tumour tissue,
82% [28]: the number of protons in the water molecule,
nH2O, is 2, and that in the Cho group, nCho, is 9. MwH2O
represents the molecular weight of water.
The T1 and T2 saturation factors for water and Cho were
calculated using literature values for T1 and T2 relaxation
times of water and Cho as described elsewhere [38].
Statistical analysis
Breast lesions that MRI classified as BI-RADS 2 were
considered benign and BI-RADS 3, 4 and 5 lesions were
considered positive for malignancy. Sensitivity, specificity,
positive predictive values (PPV), and negative predictive
values (NPV) of breast contrast-enhanced MRI were
calculated on the basis of final histopathology reports.
The mean and standard deviation of the highest Cho
concentration of all benign and malignant lesions were
calculated. Differences between the highest Cho measure-
ments of benign and malignant breast lesions were tested
for significance using the independent sample T test. A P
value <0.05 was considered as statistically significant.
Receiver operating characteristics (ROC) analysis was used
to quantify the diagnostic accuracy of contrast-enhanced
MRI and multivoxel MR spectroscopy in the assessment of
breast lesions. Data were analysed in SPSS 16.0 (SPSS,
Chicago, IL, USA) and STATA SE version 11.0 (STATA,
College Station, TX, USA).
Results
The indication for undergoing mammographic examination
was a palpable breast lesion in 17 (68.0%) patients. In 3
(12.0%) patients a suspicious lesion was found during the
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National Dutch Breast Cancer Screenings Programme.
Three (12.0%) patients were screened because of a high
risk of breast cancer. Two (8.0%) patients had a mammog-
raphy because of an enlarged lymph node in the axilla.
Breast lesions
Twenty-six breast lesions were assessed (1 patient had both
a mammographic BI-RADS 3 lesion and a BI-RADS 4
lesion in the same breast). Ten (38.5%) out of 26 breast
lesions were classified as BI-RADS 3 and 16 (61.5%)
breast lesions as BI-RADS 4 on the mammogram. The size
of the benign lesions as seen on MRI varied between 10
and 21 mm. For malignant lesions the size was 10 to
80 mm.
MRI BI-RADS classification and multivoxel MR
spectroscopy
Magnetic resonance imaging re-classified the 26 breast
lesions as BI-RADS 2 (n=5; 19.2%), BI-RADS 3 (n=8;
30.8%), BI-RADS 4 (n=5; 19.2%) and BI-RADS 5 (n=8;
30.8%). The means of the highest Cho concentrations
detected in these BI-RADS categories were 1.16±0.43SD
for five BI-RADS 2 lesions, 1.43±0.47SD for eight BI-
RADS 3 lesions, 2.98±2.15SD for five BI-RADS 4 lesions
and 4.94±3.10SD for eight BI-RADS 5 lesions (Table 1).
The five MRI BI-RADS 2 lesions with a mean Cho
concentration of 1.16 mM were benign: 3 were fibroade-
nomas and 2 showed no malignant cells after FNAB.
Two out of eight MRI BI-RADS 3 lesions turned out to
be malignant and showed a mean Cho concentration of
2.05 mM. These two breast lesions were an invasive ductal
carcinoma and an invasive lobular carcinoma. The other six
MRI BI-RADS 3 lesions were benign and had a mean Cho
concentration of 1.22 mM. One out of 6 benign breast
lesions showed no malignant cells in the FNAB and the
histologies of the other five lesions were: 2 fibroadenomas,
lobular hyperplasia without atypia, epithelial hyperplasia
without atypia and fibrosis with apocrine metaplasia. There
was a significant difference in Cho concentration between
the benign and malignant breast lesions in the BI-RADS 3
category (P=0.01).
All five MRI BI-RADS 4 lesions and all eight MRI BI-
RADS 5 lesions with a mean Cho concentration of
2.98 mM and 4.94 mM, respectively, showed malignancy
after surgery: 10 invasive ductal carcinomas, 2 invasive
lobular carcinoma (Fig. 1) and 1 metaplastic carcinoma.
Furthermore, there was no overlap between the ranges in
benign [0.4–1.5 mM (1.19±0.33 SD)] and malignant
lesions [1.7–11.8 mM (4.03±2.72 SD)] (Tables 1, 2).
Breast MRI without multivoxel MR spectroscopy had
a sensitivity of 100%, specificity of 45.5%, PPV of
71.4% and NPV of 100%. ROC analysis revealed an
area under the curve (AUC) of 0.96±0.03 (95% CI:
0.91–1.00) for the accuracy of breast MRI in the
assessment of breast lesions. Using a threshold of the
Cho concentration of 1.5 mM as the distinction between
benign and malignant lesions, the ROC analysis for
multivoxel MR spectroscopy revealed an AUC of 1.00
(95% CI: 1.00–1.00) (Fig. 2).
Discussion
Breast MRI is an important diagnostic technique and with
an NPV of 97% [4–6] it can safely exclude malignancy.
Also, in this study the NPV of breast MRI is very high
(100%) and therefore no further invasive diagnostic work-
up is needed when breast lesions are assessed as BI-RADS
2 with MRI. However, breast MRI is still not perfect. Today
BI-RADS is the communication tool in breast MRI reports
and the most difficult breast lesions are those that are
classified as BI-RADS 3 with MRI. The probability of a
mammographic BI-RADS 3 lesion being cancerous is
considered to be less than 2% by AHQR [11], but the
acceptable cancer yield is not clearly defined for MRI BI-
RADS 3 lesions. There are five articles that included data in
the MRI BI-RADS 3 assessment category, with a resulting
wide range of cancer yields (0.6–10%) [4, 43–46].
Table 1 MRI BI-RADS classification, number of voxels and the mean and standard deviation (SD) of the highest Cho concentration in benign
and malignant breast lesions
MRI BI-RADS classification
(number of benign+malignant lesions)
Number of
voxels (range)
Highest Cho concentration (mM) (mean±SD)
All Benign Malignant P value
5 BI-RADS 2 lesions (5+0) 2–6 1.16±0.43 1.16±0.43
8 BI-RADS 3 lesions (6+2) 2–6 1.43±0.47 1.22±0.26 2.05±0.35 0.01
5 BI-RADS 4 lesions (0+5) 2–7 2.98±2.15 2.98±2.15
8 BI-RADS 5 lesions (0+8) 3–14 4.94±3.10 4.94±3.10
Total 1.19±0.33 4.03±2.72 0.01
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Although the diagnostic work-up of a BI-RADS 3 lesion
can be a biopsy (instead of a follow-up breast MRI after
6 months) over 90% of patients who are referred for biopsy
have a benign disease.
Fig. 1 Volume of interest (36 voxels of 0.25 cm3 each) centred on an
invasive lobular carcinoma in the right breast of a 67-year-old patient
and spectral map showing intense water and minor fat peaks in the
lesion (a). This array of unsuppressed spectra is shown for the
chemical shift range of 0–6 ppm. After application of water and fat
suppression intense Cho signals are detected in the whole lesion as
shown in green on the metabolic map (b). The highest detected Cho
level (the red voxel on the metabolic map) is used for quantification.
The sum of all tumour MR spectra together is shown in (c) where the
fit for Cho is shown in red (range 2–4.5 ppm)











10 BI-RADS 3 4 BI-RADS 2 6 0.4 Fibroadenoma
2 1.3 Fibroadenoma
2 1.3 No malignant cells
4 1.5 No malignant cells
5 BI-RADS 3 6 1.3 Fibroadenoma
2 1.3 Fibroadenoma
4 1.5 Fibrosis with apocrine metaplasia
4 1.0 Lobular hyperplasia without atypia
4 0.8 No malignant cells
1 BI-RADS 4 4 2.4 Invasive ductal carcinoma
16 BI-RADS 4 1 BI-RADS 2 2 1.3 Fibroadenoma
3 BI-RADS 3 5 1.4 Epithelial hyperplasia without atypia
2 1.8 Invasive ductal carcinoma
2 2.3 Invasive lobular carcinoma
4 BI-RADS 4 2 1.7 Invasive ductal carcinoma
2 1.8 Invasive ductal carcinoma
3 2.2 Invasive ductal carcinoma
7 6.8 Invasive ductal carcinoma
8 BI-RADS 5 3 2.5 Invasive ductal carcinoma
4 4.1 Invasive ductal carcinoma
4 2.4 Invasive ductal carcinoma
6 4.6 Invasive ductal carcinoma
4 6.8 Invasive ductal carcinoma
5 11.8 Invasive lobular carcinoma
14 3.4 Invasive lobular carcinoma (Fig. 1)
7 3.9 Metaplastic carcinoma
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This present study indicates that the non-invasive
quantitative multivoxel MR spectroscopic technique can
be an additional tool to contrast-enhanced MRI in the
assessment of breast lesions. The accuracy of breast
MRI is excellent, but according to our preliminary
results multivoxel MR spectroscopy shows an AUC of
1.00. There was no overlap between the outcomes of
benign and malignant lesions for the highest Cho
concentration, 0.4–1.5 mM and 1.7–11.8 mM, respec-
tively. Cho concentrations over 1.5 mM are not found
in benign lesions, such as fibroadenomas. In our study
benign breast lesions that were classified as BI-RADS 3
with MRI had a highest Cho concentration ≤1.5 mM
and were significantly different (P=0.01) from the two
malignant BI-RADS 3 lesions. In this way patients with
benign BI-RADS 3 lesions can be excluded from further
invasive diagnostic work-ups. Accordingly, it can be
expected that the added value of non-invasive multivoxel
MR spectroscopy applies to the MRI-classified BI-RADS
3 lesions.
There are only three previous studies featuring the
diagnostic value of combined contrast-enhanced MRI and
multivoxel MR spectroscopy in evaluating breast lesions.
The conclusion of these three studies is that multivoxel MR
spectroscopy appears to be a promising technique for the
classification of breast lesions when contrast-enhanced MRI
results are equivocal. Since the goal of contrast-enhanced
MRI is to reach high sensitivity at the cost of specificity, the
metabolic information measured by multivoxel MR spec-
troscopy may be used to improve the specificity in the
diagnosis of breast tumours [34, 36, 37]. In the study of
Baek et al. [34] multivoxel MR spectroscopy had a
sensitivity of 81%, specificity of 78% and overall accuracy
of 81% with the use of ROC analysis. These outcomes
show lower sensitivity and specificity than the results in our
study. A limitation of the three studies is that the area of the
Cho was measured in the lesion and expressed relative to
the background noise level (signal-to-noise ratio), which is
not a quantitative measurement of Cho [34, 36, 37]. In our
quantitative multivoxel MR spectroscopic study the detect-
ability of abnormalities in the Cho level is improved by the
measurement of the highest lesion Cho concentration with
the ability to analyse the regional distribution of tumour
metabolites.
A limitation of our study is that a small patient
population is included. Another limitation is that only
breast lesions ≥1 cm3 were included, reflecting the
limited sensitivity of MR spectroscopy (voxels sixes were
0.25 cm3). Smaller breast lesions will have the problem
that the measured lesion Cho levels are reduced by partial
volume effects, reducing the changes of being able to
demonstrate a malignant Cho profile. In the future, the use
of more sensitive MRI systems operating at 3 T and higher
may be expected to allow for the inclusion of smaller
lesions. Also, in this study the breast lesions were
measured by MR spectroscopy with DWI and T2-
weighted imaging based positioning of the VOI and not
planned on the contrast-enhanced T1-weighted images,
acquired after the MR spectroscopy to avoid the likely
influence of contrast medium on the measured Cho
concentration. This can be a problem if the breast lesion
is not visible with the first two sequences (DWI and T2).
Furthermore, the methodology of this study has some
technical limitations regarding partial volume effects,
water and fat suppression, whole breast coverage in
acceptable imaging times and quantification. Neverthe-
less, in this quantitative multivoxel MR spectroscopic
study Cho concentrations are measured more accurately
and a significant difference (P=0.01) between benign and
malignant lesions for the highest Cho concentration is
shown.
In conclusion, this study indicates that the non-
invasive quantitative multivoxel MR spectroscopic tech-
nique can improve the accuracy of contrast-enhanced
MRI in the assessment of breast lesions, especially for
breast lesions classified as BI-RADS 3. A Cho concen-
tration over 1.5 mM was not found in benign breast
lesions with a volume ≥1 cm3 and therefore these lesions
can be excluded from further diagnostic work-up. Never-
theless, larger patient samples are needed to reinforce these
conclusions.
Fig. 2 ROC curves for the comparison of breast MRI and multivoxel
MR spectroscopy in the assessment of breast lesions. There was a
significant difference in the Cho concentrations between all benign
and malignant lesions (P=0.01)
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